- Home
- KROS vs NGEN Comparison
KROS vs NGEN Comparison
Compare KROS & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | NGEN |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 197.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KROS | NGEN |
|---|---|---|
| Price | $11.26 | $2.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $21.86 | $18.00 |
| AVG Volume (30 Days) | 277.5K | ★ 873.0K |
| Earning Date | 05-06-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $243,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,751.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.69 | $1.70 |
| 52 Week High | $22.55 | $5.93 |
Technical Indicators
Market Signals| Indicator | KROS | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 46.23 |
| Support Level | $10.64 | $1.70 |
| Resistance Level | $11.55 | $2.35 |
| Average True Range (ATR) | 0.50 | 0.17 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 85.91 | 64.35 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.